Methods and compositions for diagnosis and treatment of cancer

Abstract

The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of tumor tissues such as ovarian tumor and lung tumor tissues and which represent targets for therapy or diagnosis of tumor diseases in a subject.

1 - 23 . (canceled) 
     
     
         24 . A method of treating a patient having a tumor disease that expresses a tumor antigen encoded by a nucleic acid sequence according to SEQ ID NO: 1 or a variant of said nucleic acid sequence,
 wherein the method comprises administering to the patient a pharmaceutical composition comprising an antibody that specifically binds a tumor antigen encoded by a nucleic acid according to SEQ ID NO: 1, wherein the tumor disease is selected from the group consisting of ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, head and neck cancer, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, small bowel cancer, uterine cancer, and metastatic forms thereof.   
     
     
         25 . The method of  claim 24 , wherein the tumor disease is ovarian cancer. 
     
     
         26 . The method of  claim 25 , wherein the ovarian cancer is metastatic ovarian cancer. 
     
     
         27 . The method of  claim 25 , wherein the ovarian cancer is ovarian adenocarcinoma or ovarian teratocarcinoma. 
     
     
         28 . The method of  claim 24 , wherein the tumor disease is lung cancer. 
     
     
         29 . The method of  claim 28 , wherein the lung cancer is metastatic lung cancer. 
     
     
         30 . The method of  claim 28 , wherein the lung cancer is small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), squamous cell lung carcinoma or adenocarcinoma. 
     
     
         31 . The method of  claim 24 , wherein the antibody is a monoclonal, chimeric, human or humanized antibody, or is an antigen binding fragment of an antibody or a synthetic antibody. 
     
     
         32 . The method of  claim 24 , wherein the antibody is a monoclonal, chimeric, human or humanized antibody. 
     
     
         33 . The method of  claim 24 , wherein the antibody is attached to one or more therapeutic effector moieties selected from the group consisting of a radiolabel, cytotoxin, and cytotoxic enzyme. 
     
     
         34 . A method of treating a patient who has been diagnosed with a tumor disease associated with a tumor antigen comprising an amino acid sequence encoded by a nucleic acid sequence of SEQ ID NO: 1 or a variant of said nucleic acid sequence,
 wherein the method comprises administering to the patient a pharmaceutical composition comprising an antibody that specifically binds a tumor antigen encoded by a nucleic acid according to SEQ ID NO: 1, wherein the tumor disease is selected from the group consisting of ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, head and neck cancer, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, small bowel cancer, uterine cancer, and metastatic forms thereof.   
     
     
         35 . The method of  claim 34 , wherein the tumor disease is ovarian cancer. 
     
     
         36 . The method of  claim 35 , wherein the ovarian cancer is metastatic ovarian cancer. 
     
     
         37 . The method of  claim 35 , wherein the ovarian cancer is ovarian adenocarcinoma or ovarian teratocarcinoma. 
     
     
         38 . The method of  claim 34 , wherein the tumor disease is lung cancer. 
     
     
         39 . The method of  claim 38 , wherein the lung cancer is metastatic lung cancer. 
     
     
         40 . The method of  claim 38 , wherein the lung cancer is small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), squamous cell lung carcinoma or adenocarcinoma. 
     
     
         41 . The method of  claim 34 , wherein the antibody is a monoclonal, chimeric, human or humanized antibody, or is an antigen binding fragment of an antibody or a synthetic antibody. 
     
     
         42 . The method of  claim 34 , wherein the antibody is a monoclonal, chimeric, human or humanized antibody. 
     
     
         43 . The method of  claim 34 , wherein the antibody is attached to one or more therapeutic effector moieties selected from the group consisting of a radiolabel, cytotoxin, and cytotoxic enzyme.